注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   NOGGIN, Human   

NOGGIN, Human

     
  • 产品详情
  • 实验流程
Product Information
Species Human
Sequence MQHYLHIRPA PSDNLPLVDL IEHPDPIFDP KEKDLNETLL RSLLGGHYDP GFMATSPPED
RPGGGGGAAG GAEDLAELDQ LLRQRPSGAM PSEIKGLEFS EGLAQGKKQR
LSKKLRRKLQ MWLWSQTFCP VLYAWNDLGS RFWPRYVKVG SCFSKRSCSV
PEGMVCKPSK SVHLTVLRWR CQRRGGQRCG WIPIQYPIIS ECKCSC
Purity > 95 % by SDS-PAGE and HPLC analyses.
Endotoxin Level Less than 1 EU/ µg of rHuNoggin as determined by LAL method.
Formulation Lyophilized from a 0.2 µm filtered concentrated solution in 30 % acetonitrile, 0.1 % TFA.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 10mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Additional Information
Target Background Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-ß family and regulate their activity by inhibiting their access to signaling receptors. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis.
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价